Therapy Detail

Therapy Name AZ-TAK1
Therapy Description

AZ-TAK1 is an ATP-competitive inhibitor of TAK1, which may result in apoptotic activity and inhibition of cell growth in cancer cells (PMID: 22649101).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AZ-TAK1 AZ-TAK1 is an ATP-competitive inhibitor of TAK1, which may result in apoptotic activity and inhibition of cell growth in cancer cells (PMID: 22649101).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant colon cancer sensitive AZ-TAK1 Preclinical - Cell culture Actionable In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129). 27655129
KRAS G12V colon cancer sensitive AZ-TAK1 Preclinical - Cell culture Actionable In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129). 27655129
Clinical Trial Phase Therapies Title Recruitment Status